Notable Labs (NTBL) Announces CEO Transition

Go back to Notable Labs (NTBL) Announces CEO Transition

Notable Labs Announces CEO Transition

August 26, 2024 4:05 PM EDT

Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO

Company affirms plan to initiate volasertib Phase 2 program in the coming months

FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (Notable, Notable Labs or the Company), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company,... More